Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01613599 · ClinicalTrials.gov registry record
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
A clinical trial, sponsored by Genentech.
- Completed
- Registry status
- 100
- Enrollment target
NCT01613599 is a clinical trial that has completed, run by Genentech. The registered enrollment target is 100 participants.
The verdict
NCT01613599 has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
This prospective observational study will evaluate the long-term safety of MabThera/Rituxan (rituximab) in participants with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis. Data will be collected for a maximum of 4 years from participants initiated on MabThera/Rituxan therapy by their physician according to prescribing information.
Interventions
- DRUG Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2012-06-20 |
| Est. Completion | 2017-04-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01613599
The ClinicalTrials.gov registry entry for NCT01613599 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rituximab is the first listed.
NCT01613599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01613599 about?
NCT01613599 is a clinical study titled "An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis". This prospective observational study will evaluate the long-term safety of MabThera/Rituxan (rituximab) in participants with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis. Data will be collected for a maximum of 4 years from participants initiated on MabThera/Rituxan thera...
What is the current status of trial NCT01613599?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2012-06-20. Estimated completion is 2017-04-28.
What interventions are being tested in trial NCT01613599?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT01613599?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.